Last $14.21 USD
Change Today +0.30 / 2.16%
Volume 1.1M
KERX On Other Exchanges
Symbol
Exchange
KERX is not on other exchanges.
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

keryx biopharmaceuticals (KERX) Snapshot

Open
$13.97
Previous Close
$13.91
Day High
$14.44
Day Low
$13.95
52 Week High
03/31/14 - $17.46
52 Week Low
08/19/13 - $8.29
Market Cap
1.3B
Average Volume 10 Days
1.3M
EPS TTM
$-0.69
Shares Outstanding
91.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KERYX BIOPHARMACEUTICALS (KERX)

keryx biopharmaceuticals (KERX) Related Bloomberg News

View More Bloomberg News

keryx biopharmaceuticals (KERX) Related Businessweek News

No Related Businessweek News Found

keryx biopharmaceuticals (KERX) Details

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis. Zerenex has also completed a Phase II study for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with stages three to five non-dialysis dependent chronic kidney disease. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

59 Employees
Last Reported Date: 05/8/14
Founded in 1997

keryx biopharmaceuticals (KERX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $475.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2013.

keryx biopharmaceuticals (KERX) Key Developments

Keryx Biopharmaceuticals Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 03:00 PM

Keryx Biopharmaceuticals Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 03:00 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Ron Bentsur, Chief Executive Officer, Director and Member of Research & Development Committee.

Keryx Receives Notification of PDUFA Date Extension for Zerenex(TM)

Keryx Biopharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) goal date for its review of the Company's New Drug Application (NDA) seeking marketing approval of Zerenex(TM) (ferric citrate) by three months. The new PDUFA goal date is September 7, 2014. The notification letter from the FDA states that the Company's recent submission, in response to a Chemistry, Manufacturing and Controls (CMC) section information request from the FDA, included substantial revisions to the CMC section of the NDA. The FDA considered the submission to be a major amendment to the NDA and is extending the goal date by three months to provide time for a full review of the submission.

Keryx Biopharmaceuticals Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-12-2014 10:00 AM

Keryx Biopharmaceuticals Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-12-2014 10:00 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Gregory P. Madison, Chief Operating Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KERX:US $14.21 USD +0.30

KERX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KERX.
View Industry Companies
 

Industry Analysis

KERX

Industry Average

Valuation KERX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 123.1x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 111.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit www.keryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.